FAM219A

Across TCGA pan-cancer cohorts, FAM219A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM219A data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FAM219A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM219A expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

HNSC, PDAC, and GBM are the cancer types where FAM219A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.779	1.000	.003	38	view →
PDAC	DFS	Median	All	0.194	0.439	.002	23	view →
GBM	DFS	Tertile	All	0.775	0.686	.020	5	view →
LUAD	DFS	Median	All	0.676	0.936	.028	1	view →
CCRCC	DFS	Tertile	II,III,IV	1.000	0.882	.043	1	view →
LSCC	DFS	Quartile	All	0.903	0.960	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM219A–HNSC (OS)

Open the HNSC breakdown →